Lonza Group logo

Lonza Group

Stock
Stock
ISIN: CH0013841017
Ticker: LONN
CH0013841017
LONN

Price

Price

CHART BY

Historical dividends and forecast

All dividend data

 The next dividend will be paid on 15.05.2025


$3.013

CHART BY

Frequently asked questions

What is Lonza Group's market capitalization?

The market capitalization of Lonza Group is 41.04B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Lonza Group's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Lonza Group is 65.35. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Lonza Group?

Lonza Group's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $8.93. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Lonza Group's stock?

Currently, 27 analysts cover Lonza Group's stock, with a consensus target price of 665.52. Analyst ratings provide insights into the stock's expected performance.

What is Lonza Group's revenue over the trailing twelve months?

Over the trailing twelve months, Lonza Group reported a revenue of 6.57B.

Is Lonza Group paying dividends?

Yes, Lonza Group is paying dividends. The next payment is scheduled for 15.05.2025, with an expected amount of .

What is the EBITDA for Lonza Group?

Lonza Group's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is 1.49B. EBITDA measures the company's overall financial performance.

What is the free cash flow of Lonza Group?

Lonza Group has a free cash flow of -108.00M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

How many employees does Lonza Group have, and what sector and industry does it belong to?

Lonza Group employs approximately 18,686 people. It operates in the Health Care sector, specifically within the Biotechnology industry.

What is the free float of Lonza Group's shares?

The free float of Lonza Group is 68.19M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
41.04B
EPS (TTM) 
$8.93
Free Float 
68.19M
P/E ratio (TTM) 
65.35
Revenue (TTM) 
6.57B
EBITDA (TTM) 
1.49B
Free Cashflow (TTM) 
-108.00M

Pricing

1D span
$646.87$653.17
52W span
$511.49$683.30

Analyst Ratings

The price target is 665.52 and the stock is covered by 27 analysts.

Buy

22

Hold

5

Sell

0

Information

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment design, development, and manufacturing, with the ability to offer integrated drug substances to drug product solutions, including particle engineering and drug product packaging. The Cell and Gene segment develops, de-risk, commercializes, and scales their emerging therapies through its three business areas Cell and Gene Technologies, Bioscience, and Personalized Medicine. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.

Employees
18,686
Industries
Biotechnology
Sector
Health Care

Identifier

ISIN
CH0013841017
Primary Ticker
LONN

Knockouts

Finance data from FactSet
Join the conversation